We’ve come a long way since tissue biopsies were considered the go-to way to obtain samples needed to test for cancer. Breast cancer, prostate cancer, and lung cancer all required invasive methods to obtain tissue. Thankfully, liquid biopsies–whether through...
The OncobiotaLUNGdetect is a multi-species, multi-omic liquid biopsy assay that will aid clinicians in risk stratification of pulmonary nodules. Micronoma is the first company to commercialize an assay that integrates metagenomic, proteomic, clinical and radiomic...
At Micronoma we are putting everything we have into ensuring that development of diagnostics like our Oncobiota™ platform will be a key propellent for creating new opportunities in precision medicine by identifying cancer at its earliest stages. But first, a quick...
At Micronoma, we turn to science first to guide us down the road to delivering the first diagnostic platform technology using the microbiome to detect early-stage cancer. At the same time, we keep a watchful eye on our resources so we can steer clear of the...
It’s no exaggeration to say the development of Micronoma’s Oncobiota™ microbiome-driven liquid-biopsy technology to detect cancer at an early stage would not be possible without extensive expertise and use of machine learning (ML) tools. Micronoma’s proprietary...
While researchers have typically seen microbes only as contaminants and discarded them, Micronoma has set itself apart by seeing the treasure trove of opportunity microbes represent to detect and identify cancer early. Using liquid biopsy–a simple blood draw–Micronoma...
